Overview

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and tolerability of SLN360 in patients with elevated Lp(a).
Phase:
Phase 1
Details
Lead Sponsor:
Silence Therapeutics plc
Collaborator:
Medpace, Inc.